AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10323115
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg intramuscular injection at induction, followed by 50 mg tablet 4 to 6 hours after operation and 50 mg three times daily for the next 6 days
Trial: 28604089
Drug: 0.9 mL
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mL of 2% lidocaine with epinephrine 1:100,000
Trial: 28604089
Drug: 0.9 mL
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mL of 4% articaine with epinephrine 1:100,000
Trial: 26493267
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and Carboplatin intercalated with Gefitinib (PCG) - P 175 mg/m², C AUC 5 on day 1, G 250 mg orally on days 2-15 for four cycles followed by G 250 mg orally until progressive disease.
Trial: 26493267
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and Carboplatin alone (PC) - same dosing schedule for four cycles only.
Trial: 11248662
Drug: Clodronate 800
RxNorm normalized name: clodronic acid 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 800 mg daily by mouth
Trial: 8996143
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 every 3 weeks plus Cyclophosphamide 750 mg/m2 (CC group, n = 22)
Trial: 8996143
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 every 3 weeks plus Paclitaxel 175 mg/m2 over a 3-hour infusion (CP group, n = 24)
Trial: 8996143
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus Cyclophosphamide (CC group)
Trial: 8490639
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control classes
Trial: 24864486
Drug: sylvinite speleoclimatotherapy
RxNorm normalized name: Sylvite
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sylvinite speleoclimatotherapy (10 sessions, 60 min each) in addition to conventional pharmacotherapy
Trial: 24864486
Drug: traditional medicamental
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: traditional medicamental therapy alone
Trial: 23402084
Drug: TAC-Short-term (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-Short-term (2 mo) low-dose steroid (STER)
Trial: 23402084
Drug: Rejection treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rejection treatment
Trial: 16248241
Drug: Modified Qingwen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Qingwen Baidu Decoction (MQBD) in addition to conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Trial: 16248241
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Trial: 10960643
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 200 microg
Trial: 7636057
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (10 mg/body square meters)
Trial: 3295623
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm 1
Trial: 3295623
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm 2
Trial: 335867
Drug: Trimazosin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin (300 and 450 mg daily)
Trial: 28699044
Drug: Narrowband UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narrowband UVB (NB‐UVB) therapy
Trial: 20495919
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose capecitabine (CCB 1) 1,250 mg/m² p.o. twice daily for 2 weeks
Trial: 20495919
Drug: Dose-intensified capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose-intensified capecitabine (CCB 2) 1,750 mg/m² p.o. twice daily for 1 week
Trial: 9370898
Drug: Hydrocortisone 25
RxNorm normalized name: hydrocortisone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 25 mg/m2
Trial: 9370898
Drug: Hydrocortisone 15
RxNorm normalized name: hydrocortisone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 15 mg/m2
Trial: 1555625
Drug: SR-verapamil 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR-verapamil 360 mg o.d.
Trial: 1555625
Drug: nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 20 mg t.d.s.
Trial: 27883209
Drug: Traditional dysphagia
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional dysphagia therapy
Trial: 30676426
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (rTMS + traditional dysphagia therapy)
Trial: 28807635
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (n=183)
Trial: 28807635
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg with laser (n=180)
Trial: 28807635
Drug: Laser (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser (with optional ranibizumab 0.5 mg after month 6; n=92)
Trial: 27039022
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg with laser
Trial: 31808278
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg monotherapy
Trial: 28807635
Drug: Laser (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser (monotherapy and combined with ranibizumab from month 6)
Trial: 26318715
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine and Placebo
Trial: 20461382
Drug: PX-12 (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-12 (54 or 128 mg/m²) administered by 3-hour IV infusion daily for 5 days every 21 days
Trial: 20461382
Drug: PX-12 (128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-12 (128 mg/m²)
Trial: 20461382
Drug: PX-12 (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PX-12 (54 mg/m²)
Trial: 11007235
Drug: Commercial kit
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial kit for antitissue transglutaminase antibodies (INOVA Diagnostics, Inc.)
Trial: 11007235
Drug: Antiendomysial antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiendomysial antibody
Trial: 11007235
Drug: Antitissue transglutaminase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitissue transglutaminase antibodies (blind determination)
Trial: 8770996
Drug: Cyclosporine (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (treatment duration > or = 24 months)
Trial: 8770996
Drug: Cyclosporine (GFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (GFR < or = 50 ml/min/1.73 m2)
Trial: 1478285
Drug: Regional isolated
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional isolated perfusion as adjuvant treatment
Trial: 31453489
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy group (n=52)
Trial: 10883872
Drug: CHX spray
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHX spray
Trial: 1443446
Drug: Formalinized depot
RxNorm normalized name: formalin
DrugBank: Formaldehyde (DB03843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formalinized depot grass allergoid (cumulative pre-seasonal dosage of 46,050 PNU)
Trial: 29925930
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rituximab with therapy targeting CD4+ T cells
Trial: 27890801
Drug: EUS-guided paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EUS-guided paclitaxel injection (PTX) plus standard of care (SOC)
Trial: 25720672
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 capsules once weekly for 8 weeks
Trial: 25720672
Drug: Starch capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch capsules (placebo) once weekly for 8 weeks
Trial: 21819556
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 17.5 mg weekly
Trial: 21819556
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2.5 mg/kg daily
Trial: 11464310
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg daily for 3 weeks
Trial: 2563616
Drug: Grenz ray
RxNorm normalized name: Ray Dol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grenz ray therapy (5 Gy applied on 10 occasions at intervals of 1 week)
Trial: 799988
Drug: Imipramine (Tofranil)
RxNorm normalized name: imipramine hydrochloride Oral Solution [Tofranil]
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine (Tofranil) added to standard analgesic anti-rheumatic therapy
Trial: 27932679
Drug: NSAIDs (ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ibuprofen 1,200 mg/day)
Trial: 16729788
Drug: Montelukast (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (4 mg tablet)
Trial: 3093221
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg enoxacin
Trial: 3093221
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg enoxacin
Trial: 28139405
Drug: Idelalisib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib (150 mg orally twice daily) in combination with bendamustine and rituximab
Trial: 28139405
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with bendamustine and rituximab
Trial: 20507568
Drug: Interspinous implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interspinous implant surgery
Trial: 18790154
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive treatment for rectal cancer
Trial: 16263817
Drug: 4.4 mg
RxNorm normalized name: pectin 4.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 mg testosterone gel
Trial: 16263817
Drug: 8.8 mg
RxNorm normalized name: menthol 8.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.8 mg testosterone gel
Trial: 16263817
Drug: 13.2 mg
RxNorm normalized name: menthol 13.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.2 mg testosterone gel
Trial: 16263817
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg testosterone gel
Trial: 16263817
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of testosterone gel
Trial: 12684146
Drug: NuvaRing with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuvaRing with nonoxynol‐9 co-medication
Trial: 11027905
Drug: Ketamine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.50 mg/kg
Trial: 8156509
Drug: Continuous hyperthermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperthermic peritoneal perfusion (CHPP) with 10 micrograms/ml mitomycin C
Trial: 3168696
Drug: pH-sensitive enteric-coated
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-sensitive enteric-coated pancreatic enzyme preparation
Trial: 3168696
Drug: Conventional enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional enzyme preparations
Trial: 30033855
Drug: Daily dysmenorrhea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dysmenorrhea and nonmenstrual pelvic pain impact items
Trial: 28138971
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis administration (6.9% [50.4 mg] THC)
Trial: 24059116
Drug: rTMS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS treatment for 2 weeks (15 days) combined with selective serotonin reuptake inhibitor (SSRI)
Trial: 24059116
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (SSRI) only
Trial: 18974308
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (cognitive behavioral therapy + sertraline)
Trial: 18974308
Drug: Sertraline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (up to 200 mg per day)
Trial: 9032569
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies
Trial: 10852274
Drug: i.v. clodronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. clodronate 300 mg daily for 10 consecutive days
Trial: 6784264
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active drugs (Propranolol, Atenolol, Metoprolol)
Trial: 6784264
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (including placebo)
Trial: 23398944
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d lutein
Trial: 21290392
Drug: 940 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 940 nm laser treatment (GR1)
Trial: 21290392
Drug: Topical PA
RxNorm normalized name: Mega Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical PA agent indocyanine-green followed by 810 nm laser treatment (GR2)
Trial: 19118130
Drug: Distributed Constraint-Induced
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed Constraint-Induced Therapy (CIT)
Trial: 9770738
Drug: Diltiazem (60-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60-90 mg 4 times a day)
Trial: 9770738
Drug: Nifedipine (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20-30 mg 4 times a day)
Trial: 9770738
Drug: Diltiazem (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (single dose)
Trial: 3066967
Drug: Nifedipine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (single dose)
Trial: 9770738
Drug: Nifedipine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (long-term treatment)
Trial: 9770738
Drug: Diltiazem (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (long-term treatment)
Trial: 7885111
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose chemotherapy
Trial: 30658935
Drug: PET-driven treatment
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-driven treatment (ABVD after positive PET2 or BEACOPPescalated after negative PET2)
Trial: 30658935
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (BEACOPPescalated for all cycles)
Trial: 30658935
Drug: PET-driven treatment
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-driven treatment (ABVD after positive PET2)
Trial: 30658935
Drug: PET-driven treatment
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-driven treatment
Trial: 22584456
Drug: Adjunctive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive telephone coaching and electronic contact (ATC) with the Loozit group program (n=73)
Trial: 21414746
Drug: Metal-backed modular
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal-backed modular version of the implant
Trial: 16761192
Drug: Rilmenidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine (0.5 mg)
Trial: 9339113
Drug: IVIG (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (500 mg/kg for >1500 g, 700 mg/kg for <1500 g) on days 1, 2, and 8
Trial: 29661678
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg kg‐1; group PP)
Trial: 29661678
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (1.3 mg kg‐1 minute‐1; group SI)
Trial: 19020919
Drug: Antioxidants (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (600 mg vitamin E and 1,000 mg vitamin C daily)
Trial: 15480278
Drug: Methotrexate-mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate-mifepristone (600 mg given orally)
Trial: 15480278
Drug: Methotrexate-mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate-mifepristone (600 mg given orally) with progesterone level 10 ng/l
Trial: 15480278
Drug: Methotrexate-placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate-placebo with progesterone level 10 ng/l
Trial: 9636863
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fluconazole (200 mg once a day for 2 months) and flucytosine (150 mg/(kg.d) for the first 2 weeks)
Trial: 9636863
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fluconazole and flucytosine
Trial: 9636863
Drug: Fluconazole monotherapy
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole monotherapy (200 mg once a day for 2 months)
Trial: 3363288
Drug: Single intraduodenal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraduodenal dose of camostate
Trial: 3363288
Drug: Daily ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of camostate for 5 days
Trial: 435882
Drug: Chenic acid
RxNorm normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenic acid (14‐16 mg/kg/day) administered at bedtime
Trial: 435882
Drug: Chenic acid
RxNorm normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenic acid (14‐16 mg/kg/day) administered in the morning
Trial: 435882
Drug: Chenic acid
RxNorm normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenic acid (14‐16 mg/kg/day) administered at mealtimes
Trial: 30351172
Drug: Combined RM
RxNorm normalized name: morphine sulfate Rectal Suppository [RMS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined RM + Relaxation Lighting (RM+L)
Trial: 30351172
Drug: Combined Music
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Music + Relaxation Lighting (M+L)
Trial: 28291511
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (2 mg/mL)
Trial: 28291511
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (2 mg/mL) with morphine (1 mg/mL)
Trial: 23603619
Drug: Low-volume strength
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume strength training (1 set, twice weekly for 13 weeks)
Trial: 23603619
Drug: High-volume strength
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume strength training (3 sets, twice weekly for 13 weeks)
Trial: 11500288
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of open-ended test questions by computer